

**RECORDATI: PUBLICATION OF DOCUMENTATION RELATED TO THE REVERSE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.**

Milan, 13th November 2020 – Following the press release issued on 1st October 2020, please be informed that the following documentation related to the reverse merger by absorption of Rossini Investimenti S.p.A. and FimeI S.p.A. into Recordati S.p.A. (the “**Merger**”) is available to the public, as of today, at the Company’s registered office, on the Company’s website (www.recordati.it, in the area “*Investors*”, section “*Shareholders’ Meetings – Reverse Merger into Recordati S.p.A. 2020/2021*”) and on the “1INFO” storage mechanism (www.1info.it):

- the Explanatory Report of the Board of Directors of each participant in the Merger drawn up pursuant to section 2501-quinquies of the Italian Civil Code, and, with regard to Recordati, section 70, paragraph 2, of the regulation adopted by Consob by resolution No. 11971 of 14 May 1999, in accordance with form 1 of the relevant Annex 3A; and
- the Report on the exchange ratio drawn up by PricewaterhouseCoopers SpA, as common expert appointed by the Court pursuant to section 2501-sexies of the Italian Civil Code.

The last three (with reference to Rossini Investimenti, having the latter been incorporated in 2018, the last two) adopted financial statements of the Merging Companies (together with the reports of the subjects entrusted with the management and accounting audit of such companies) are also available to the public in the manner described above.

Lastly, please be informed that the Presidency of the Council of Minister - to which the Merger was notified pursuant to Legislative Decree No. 21/2012, converted with Law No. 56/2012, communicated the closure of the procedure pursuant to art. 8 of the Prime Ministerial Decree of 6 August 2014, not exercising the special powers provided for by the aforementioned legislation (so-called Golden Power).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150
CODICE FISCALE/P. IVA 00748210150
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l